Kei Muro

1997–2025 年に発表

178
論文数
38,056
被引用数
81
h 指数
170
i10 指数

被引用数

Kei Muro の年別被引用数1991 年: 被引用 3 件1995 年: 被引用 1 件1997 年: 被引用 6 件1999 年: 被引用 3 件2000 年: 被引用 5 件2001 年: 被引用 6 件2002 年: 被引用 19 件2003 年: 被引用 21 件2004 年: 被引用 26 件2005 年: 被引用 33 件2006 年: 被引用 35 件2007 年: 被引用 36 件2008 年: 被引用 39 件2009 年: 被引用 50 件2010 年: 被引用 40 件2011 年: 被引用 35 件2012 年: 被引用 69 件2013 年: 被引用 74 件2014 年: 被引用 130 件2015 年: 被引用 164 件2016 年: 被引用 163 件2017 年: 被引用 300 件2018 年: 被引用 349 件2019 年: 被引用 1,532 件2020 年: 被引用 2,132 件2021 年: 被引用 2,002 件2022 年: 被引用 1,539 件2023 年: 被引用 1,090 件2024 年: 被引用 1,743 件2025 年: 被引用 767 件2026 年: 被引用 24 件1992〜1994 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 2,335 件、この内訳の 17.8%アメリカ合衆国: 引用元論文 2,200 件、この内訳の 16.8%日本: 引用元論文 1,710 件、この内訳の 13%イタリア: 引用元論文 772 件、この内訳の 5.9%イギリス: 引用元論文 589 件、この内訳の 4.5%ドイツ: 引用元論文 549 件、この内訳の 4.2%フランス: 引用元論文 470 件、この内訳の 3.6%韓国: 引用元論文 444 件、この内訳の 3.4%スペイン: 引用元論文 400 件、この内訳の 3%オランダ: 引用元論文 338 件、この内訳の 2.6%カナダ: 引用元論文 253 件、この内訳の 1.9%ベルギー: 引用元論文 218 件、この内訳の 1.7%
0%17.8%その他 21.6%

分野

  • Medicine75.4%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Materials Science3.5%
  • Immunology and Microbiology3.4%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Neuroscience0.7%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers9.9%
  • Gastric Cancer Management and Outcomes7%
  • Colorectal Cancer Treatments and Studies6.2%
  • Esophageal Cancer Research and Treatment4.4%
  • Colorectal Cancer Surgical Treatments3.3%
  • Genetic factors in colorectal cancer2.4%
  • その他66.8%

共著者

全論文

検索で開く
  1. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 2,279

  2. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 被引用: 1,812

  3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 被引用: 3,449

  4. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hiroyuki Uetake, Shigeki Yamaguchi, Naohiko YAMAGUCHI, Hirotoshi Kobayashi, Keiji Matsuda, Kenjiro Kotake, Kenichi Sugihara, Japanese Society for Cancer of the Colon and Rectum - International Journal of Clinical Oncology 2019 被引用: 1,958

  5. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 1,176

  6. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2014 被引用: 2,471

  7. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Genichi Nishimura, Yuh Sakata, Yasuhiro Shimada, Keiichi Takahashi, Shinji Tanaka, Osamu Tsuruta, Toshiharu Yamaguchi, Naohiko YAMAGUCHI, Toshiaki Tanaka, Kenjiro Kotake, Kenichi Sugihara - International Journal of Clinical Oncology 2017 被引用: 2,490

  8. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay ほか 58 名 - The Lancet 2018 被引用: 1,316

  9. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

    著者: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 被引用: 443

  10. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 288

  11. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2023 被引用: 258

  12. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 被引用: 583

  13. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

    著者: , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2018 被引用: 456

  14. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 1,131

  15. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Van Cutsem - ESMO Open 2023 被引用: 161

  16. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 859

  17. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 592

  18. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 82

  19. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 197

  20. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

    著者: , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2021 被引用: 166

  21. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

    著者: , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 152

  22. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takayuki Yoshino - Nature Medicine 2024 被引用: 110

  23. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

    著者: , , , , , , , , , , , - Future Oncology 2022 被引用: 133

  24. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2019 被引用: 231